Cost-Effectiveness Analysis of Amlodipine–Candesartan and Amlodipine–Furosemide in Hypertensive Inpatients at RSUD Dr. Loekmono Hadi Kudus, 2023
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) · 2026
DOI: 10.22146/jmpf.103302 ↗Kurz gefasst
Fachartikel in der Zeitschrift JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), 2026. Verfasst von Yulia Pratiwi und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Hypertension is a major public health problem and a leading risk factor for cardiovascular morbidity and mortality. In hospitalized patients, combination antihypertensive therapy is frequently used to achieve optimal blood pressure control, which may lead to increased healthcare costs. Therefore, evaluating the cost-effectiveness of commonly used antihypertensive combinations is essential to support rational drug selection in hospital settings.
Objectives
This study aims to analyze the cost-effectiveness of amlodipine–candesartan and amlodipine–furosemide combination therapies for inpatient hypertension treatment at RSUD dr. Loekmono Hadi Kudus in 2023.
Methods
This non-experimental, descriptive study employed a retrospective design using medical record and cost data from 88 hypertensive inpatients. Patient characteristics, length of hospital stay, therapeutic effectiveness, and direct medical costs were analyzed. Therapeutic effectiveness was defined as the proportion of patients achieving target blood pressure based on JNC VIII guidelines. Cost-effectiveness was assessed using the Average Cost-Effectiveness Ratio (ACER) and Incremental Cost-Effectiveness Ratio (ICER).
Results
The amlodipine–candesartan combination demonstrated a lower ACER (Rp48,229 per 1% effectiveness) than amlodipine–furosemide (Rp90,275). The ICER value (−Rp597,651) indicated that amlodipine–candesartan was both more effective and less costly. Higher costs in the amlodipine–furosemide group were associated with injectable drug use and a greater proportion of prolonged hospital stays.
Conclusion
Amlodipine–candesartan was more cost-effective than amlodipine–furosemide for managing hypertensive inpatients. These findings support the preferential use of amlodipine–candesartan when clinically appropriate to optimize both clinical outcomes and healthcare resource utilization.
Zitieren
APA
Pratiwi, Y., Masitoh, M. A., Rahmawaty, A., & Riyanti, M. (2026). Cost-Effectiveness Analysis of Amlodipine–Candesartan and Amlodipine–Furosemide in Hypertensive Inpatients at RSUD Dr. Loekmono Hadi Kudus, 2023. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice). https://doi.org/10.22146/jmpf.103302
Vancouver
Pratiwi Y, Masitoh MA, Rahmawaty A, Riyanti M. Cost-Effectiveness Analysis of Amlodipine–Candesartan and Amlodipine–Furosemide in Hypertensive Inpatients at RSUD Dr. Loekmono Hadi Kudus, 2023. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice). 2026. doi:10.22146/jmpf.103302
BibTeX
@article{Pratiwi2026,
author = {Pratiwi, Yulia and Masitoh, Mutia Arum and Rahmawaty, Annis and Riyanti, Mersi},
title = {Cost-Effectiveness Analysis of Amlodipine–Candesartan and Amlodipine–Furosemide in Hypertensive Inpatients at RSUD Dr. Loekmono Hadi Kudus, 2023},
journal = {JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)},
year = {2026},
doi = {10.22146/jmpf.103302}
}
EUVIMED